Enzoheal Ointment contains Mupirocin 2% w/w, a topical antibiotic effective against a range of gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is primarily indicated for the treatment of superficial skin infections such as impetigo, folliculitis, and infected eczema. Mupirocin acts by inhibiting bacterial isoleucyl-tRNA synthetase, thereby preventing protein synthesis and bacterial replication. Enzoheal Ointment is applied directly to the affected area, usually two to three times daily, for a duration of up to 10 days or as prescribed by a healthcare professional. The ointment’s formulation ensures optimal penetration and sustained antibacterial activity at the site of infection. It is generally well tolerated, with minimal systemic absorption, reducing the risk of systemic side effects. Common adverse reactions may include localized burning, stinging, or itching at the application site. Caution is advised in patients with known hypersensitivity to mupirocin or any component of the ointment. Enzoheal Ointment should not be used for viral or fungal skin infections. Proper hygiene and adherence to the prescribed regimen are essential to prevent resistance development. Consultation with a healthcare provider is recommended before initiating treatment to ensure appropriate use and to monitor therapeutic outcomes.